Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of rozanolixizumab compared with placebo in adult participants with Ocular Myasthenia Gravis. This Phase 3 randomized, double-blind, placebo-controlled study aims to better understand how rozanolixizumab affects symptoms and quality of life in adults living with this eye muscle weakness condition. Participants will be randomly assigned to receive either rozanolixizumab or a placebo through subcutaneous infusion during a 6-week intervention period. After completing the treatment phase, participants enter a 4 to 7 week observation period, during which they may have the opportunity to join an open-label extension study. Throughout the trial, participants will be closely monitored for changes in ocular symptoms and any adverse events. During the study, participants will undergo regular assessments including patient-reported outcome measures focused on ocular symptoms, quality of life, and activities of daily living. Researchers will also evaluate physical examination findings of eye muscle weakness. Safety will be monitored by tracking treatment-emergent adverse events up to 13 weeks. Overall participation may last several months, including screening, treatment, observation, and possible extension phases.